Juliane Menting1, Cees J Tack2, Arianne C van Bon3, Henry J Jansen4, Joop P van den Bergh5, Marc J T M Mol6, Martine M Goedendorp7, Rogier Donders8, Hans Knoop9. 1. Expert Centre for Chronic Fatigue, Department of Medical Psychology, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, Netherlands; Department of Medical Psychology, Radboud University Medical Centre, Nijmegen, Netherlands. 2. Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, Netherlands. 3. Department of Internal Medicine, Rijnstate Hospital, Arnhem, Netherlands. 4. Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands. 5. Department of Internal Medicine, VieCuri Medical Centre, Venlo, Netherlands; Department of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands. 6. Department of Internal Medicine, Canisius Wilhelmina Hospital, Nijmegen, Netherlands. 7. Department of Health Psychology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands. 8. Department for Health Evidence, Radboud University Medical Centre, Nijmegen, Netherlands. 9. Expert Centre for Chronic Fatigue, Department of Medical Psychology, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, Netherlands; Academic Medical Center, University of Amsterdam, Department of Medical Psychology, Amsterdam Public Health Research Institute, Amsterdam, Netherlands. Electronic address: hans.knoop@amc.uva.nl.
Abstract
BACKGROUND:Fatigue in type 1 diabetes is prevalent and persistent, but so far, no evidence-based treatments are available. We aimed to investigate the efficacy of cognitive behavioural therapy (CBT) in reducing fatigue severity in patients with type 1 diabetes. METHODS: We did a multicentre randomised controlled trial at one university medical centre and four large teaching hospitals in the Netherlands. Eligible patients were aged 18-70 years and had type 1 diabetes for at least 1 year and chronic fatigue for at least 6 months. We randomly assigned patients (1:1) to CBT or waiting list using computer-generated blocked randomisation, stratified by type of enrolment. The CBT intervention (Dia-Fit) was given for 5 months in blended form, consisting of face-to-face and web-based sessions. The primary outcome was fatigue severity assessed 5 months after randomisation, directly after the intervention or waiting list period, with the Checklist Individual Strength fatigue severity subscale. Secondary outcomes were functional impairment (assessed with the total score of the Sickness Impact Profile-8), glycaemic control (HbA1c), and glucose variability. Analyses were done by intention to treat. This trial is registered with the Nederlands Trial Register, number NTR4312. FINDINGS: Between Feb 6, 2014, and March 24, 2016, we randomly assigned 120 eligible patients to either CBT (n=60) or waiting list (n=60), all of whom were included in the intention-to-treat analyses. Compared with patients in the waiting list group, those in the CBT group had significantly lower fatigue severity scores (mean difference 13·8, 95% CI 10·0-17·5; p<0·0001) and significantly lower scores for functional impairment (mean difference 513, 95% CI 340-686; p<0·0001) after 5 months. HbA1c and glucose variability did not change after treatment and there was no difference between groups. Five patients in the CBT group and seven in the waiting list group reported adverse events; none were deemed to be related to the study intervention. INTERPRETATION: Although our findings need to be confirmed in larger and longer-term studies, they suggest that CBT can effectively reduce fatigue severity and functional impairment in type 1 diabetes. FUNDING: Dutch Diabetes Research Foundation (Diabetes Fonds).
RCT Entities:
BACKGROUND:Fatigue in type 1 diabetes is prevalent and persistent, but so far, no evidence-based treatments are available. We aimed to investigate the efficacy of cognitive behavioural therapy (CBT) in reducing fatigue severity in patients with type 1 diabetes. METHODS: We did a multicentre randomised controlled trial at one university medical centre and four large teaching hospitals in the Netherlands. Eligible patients were aged 18-70 years and had type 1 diabetes for at least 1 year and chronic fatigue for at least 6 months. We randomly assigned patients (1:1) to CBT or waiting list using computer-generated blocked randomisation, stratified by type of enrolment. The CBT intervention (Dia-Fit) was given for 5 months in blended form, consisting of face-to-face and web-based sessions. The primary outcome was fatigue severity assessed 5 months after randomisation, directly after the intervention or waiting list period, with the Checklist Individual Strength fatigue severity subscale. Secondary outcomes were functional impairment (assessed with the total score of the Sickness Impact Profile-8), glycaemic control (HbA1c), and glucose variability. Analyses were done by intention to treat. This trial is registered with the Nederlands Trial Register, number NTR4312. FINDINGS: Between Feb 6, 2014, and March 24, 2016, we randomly assigned 120 eligible patients to either CBT (n=60) or waiting list (n=60), all of whom were included in the intention-to-treat analyses. Compared with patients in the waiting list group, those in the CBT group had significantly lower fatigue severity scores (mean difference 13·8, 95% CI 10·0-17·5; p<0·0001) and significantly lower scores for functional impairment (mean difference 513, 95% CI 340-686; p<0·0001) after 5 months. HbA1c and glucose variability did not change after treatment and there was no difference between groups. Five patients in the CBT group and seven in the waiting list group reported adverse events; none were deemed to be related to the study intervention. INTERPRETATION: Although our findings need to be confirmed in larger and longer-term studies, they suggest that CBT can effectively reduce fatigue severity and functional impairment in type 1 diabetes. FUNDING: Dutch Diabetes Research Foundation (Diabetes Fonds).
Authors: Fabiola Müller; Mathilde G E Verdam; Frans J Oort; Heleen Riper; Annemieke van Straten; Irma M Verdonck-de Leeuw; Mirjam A G Sprangers; Hans Knoop Journal: Int J Behav Med Date: 2022-07-22
Authors: Manon H J Veldman; Hilde P A van der Aa; Christina Bode; Hans Knoop; Carel T J Hulshof; Marc Koopmanschap; Edwin Stavleu; Ger H M B van Rens; Ruth M A van Nispen Journal: Trials Date: 2021-12-28 Impact factor: 2.279
Authors: Madelon B Bronner; Mariëlle A C Peeters; Jane N T Sattoe; AnneLoes van Staa Journal: Health Qual Life Outcomes Date: 2020-05-12 Impact factor: 3.186
Authors: Marieke Houniet-de Gier; Heleen Beckerman; Kimberley van Vliet; Hans Knoop; Vincent de Groot Journal: Trials Date: 2020-01-20 Impact factor: 2.279
Authors: Yvonne M J Goërtz; Annemarie M J Braamse; Martijn A Spruit; Daisy J A Janssen; Zjala Ebadi; Maarten Van Herck; Chris Burtin; Jeannette B Peters; Mirjam A G Sprangers; Femke Lamers; Jos W R Twisk; Melissa S Y Thong; Jan H Vercoulen; Suzanne E Geerlings; Anouk W Vaes; Rosanne J H C G Beijers; Martijn van Beers; Annemie M W J Schols; Judith G M Rosmalen; Hans Knoop Journal: Sci Rep Date: 2021-10-25 Impact factor: 4.379